AI Bias Analysis
4 models · Takes ~15 seconds
Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
Source
Stat News
Opens original article in a new tab
(MedPage Today) -- CHICAGO -- The adjuvant treatment of RET fusion-positive non-small-cell lung cancer (NSCLC) following potentially curative surgery or radiotherapy has a new standard of care, researchers reported here. In a phase III study...
(MedPage Today) -- Peptides have moved from bodybuilding forums into the cultural mainstream. Telehealth clinics advertise them for weight loss and recovery, often outside any FDA-approved indication. Podcasters describe their personal protocols...
(MedPage Today) -- CHICAGO -- Men with metastatic castration-sensitive prostate cancer (mCSPC) and DNA repair alterations had significantly longer progression-free survival (PFS) with a targeted drug plus an androgen receptor pathway inhibitor...
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
